newsfilter
← Earnings
Earnings Releases·

Nautilus Biotechnology — Third Quarter 2026 Earnings Summary

Nautilus Biotechnology reported third-quarter 2026 revenue of $0.2 million, driven by grant revenue from The Michael J. Fox Foundation and services from its Iterative Mapping Early Access Program. Operating expenses increased by 10% to $16.9 million, resulting in a net loss of $15.6 million for the quarter. The company announced participation in the ARPA-H funded SEEDS consortium, expecting up to $6 million to deploy its Voyager Platform for Alzheimer's and cancer research. As of September 30, 2026, Nautilus held $114.3 million in cash, cash equivalents, and investments.

Company
NAUTILUS BIOTECHNOLOGY INC
Sector
Healthcare
Industry
Biotechnology